5-[2-(1,1-DiMethylethyl-d9)-5-(4-fluorophenyl)-1H-iMidazol-4-yl]-3-(2,2-diMethylpropyl)-3H-iMidazo[4,5-b]pyridin-2-aMine DiMethanesulfonate

CAS-Nr.

Englisch Name:: 5-[2-(1,1-DiMethylethyl-d9)-5-(4-fluorophenyl)-1H-iMidazol-4-yl]-3-(2,2-diMethylpropyl)-3H-iMidazo[4,5-b]pyridin-2-aMine DiMethanesulfonate

Synonyma:: LY 2228820-d9;5-[2-(1,1-DiMethylethyl-d9)-5-(4-fluorophenyl)-1H-iMidazol-4-yl]-3-(2,2-diMethylpropyl)-3H-iMidazo[4,5-b]pyridin-2-aMine DiMethanesulfonate

CBNumber:: CB42622774

Summenformel:: C26H28D9FN6O6S2

Molgewicht:: 621.792439202

MOL-Datei:: Mol file

Request For Quotation

Eigenschaften Sicherheit Verwendungswort Produktionsfirma 8

5-[2-(1,1-DiMethylethyl-d9)-5-(4-fluorophenyl)-1H-iMidazol-4-yl]-3-(2,2-diMethylpropyl)-3H-iMidazo[4,5-b]pyridin-2-aMine DiMethanesulfonate Eigenschaften

Sicherheit

5-[2-(1,1-DiMethylethyl-d9)-5-(4-fluorophenyl)-1H-iMidazol-4-yl]-3-(2,2-diMethylpropyl)-3H-iMidazo[4,5-b]pyridin-2-aMine DiMethanesulfonate Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden

Laballed LY2228820, a novel and potent p38MAPK inhibitor with potent antiinflammatory activity. LY2228820 significantly inhibited phosphorylation of MAPKAPK2 and/or HSP27, down stream targets of p38MAPK, in both multiple myeloma (MM) cell lines and LT-BMSCs. LY2228820 is a potential candidate to improve MM patient outcome both by enhancing the effect of Bortezomib (B675700) and by reducing osteoskeletal events.

5-[2-(1,1-DiMethylethyl-d9)-5-(4-fluorophenyl)-1H-iMidazol-4-yl]-3-(2,2-diMethylpropyl)-3H-iMidazo[4,5-b]pyridin-2-aMine DiMethanesulfonate Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

5-[2-(1,1-DiMethylethyl-d9)-5-(4-fluorophenyl)-1H-iMidazol-4-yl]-3-(2,2-diMethylpropyl)-3H-iMidazo[4,5-b]pyridin-2-aMine DiMethanesulfonate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 8)Lieferanten

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Chemsky (shanghai) International Co.,Ltd	021-50135380	shchemsky@sina.com	China	15421	60